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Although well characterized as a transcriptional
activator that drives prostate cancer (PCa) growth,
androgen receptor (AR) can function as a transcrip-
tional repressor, and high-level androgens can sup-
press PCa proliferation. The molecular basis for this
repression activity remains to be determined. Genes
required for DNA replication are highly enriched
among androgen-repressed genes, and AR is re-
cruited to the majority of these genes, where it
rapidly represses their transcription. This activity is
enhanced in PCa cells expressing high AR levels
and is mediated by recruitment of hypophosphory-
lated retinoblastoma protein (Rb). Significantly, AR
also indirectly increases the expression of DNA repli-
cation genes through stimulatory effects on other
metabolic genes with subsequent CDK activation
and Rb hyperphosphorylation. In castration-resis-
tant PCa cells, which are dependent on high-level
AR expression, this anti-proliferative repression
function might be exploited through treatment
with androgen in combination with agents that sup-
press AR-driven metabolic functions or cell cycle
progression.
INTRODUCTION
Androgen receptor (AR) is essential for normal prostate differen-
tiation, but in prostate cancer (PCa), it plays a pivotal role
in tumor growth. Most patients with metastatic PCa respond to
androgen deprivation therapy (ADT), but they generally relapse
within several years despite castrate androgen levels (castra-
tion-resistant prostate cancer [CRPC]) (Green et al., 2012;
Yuan et al., 2014). Residual androgens contribute to persistent
AR activity in these relapsed tumors, and many patients with966 Cell Reports 17, 966–976, October 18, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://CRPC will respond to therapies that further suppress androgen
synthesis or to new AR antagonists (de Bono et al., 2011; Scher
et al., 2012). However, these patients generally relapse within
1–2 years, and AR activity is again restored in many tumors.
Therefore, there continues to be a pressing need for new strate-
gies directed at AR in PCa.
AR has been extensively characterized as a transcriptional
activator, but it can also function as a transcriptional repressor
(Cai et al., 2011; Grosse et al., 2012; Zhao et al., 2012). Directly
AR-repressed genes include AR and AKR1C3 (an androgen
synthetic gene), revealing a negative feedback mechanism for
regulating AR signaling (Cai et al., 2011; Stanbrough et al.,
2006). This repression is dependent on LSD1, which can de-
methylate enhancer-associated mono- or di-methylated H3K4
(H3K4me1,2) (Shi et al., 2004). Significantly, high levels of andro-
gens can suppress proliferation in somemodels, including VCaP
cells (a CRPC cell line with AR gene amplification). Our previous
pathway analyses of androgen-repressed genes in VCaP
showed marked enrichment for genes involved in proliferation,
whereas AR-stimulated genes were associated with cellular
metabolism (Cai et al., 2011). Overall, these findings are consis-
tent with the role of AR in normal prostate epithelium of sup-
pressing growth and driving differentiation and suggest that
these growth-inhibitory functions of AR are overcome during
PCa development. However, the molecular mechanisms that
contribute to androgen-mediated repression of proliferation
remain to be established.
In this study, we used AR chromatin immunoprecipitation
sequencing (ChIP-seq) and transcriptome profiling to identify
genes that are directly repressed by AR. In VCaP cells, the
androgen-repressed genes with linked AR binding sites were
highly enriched for DNA replication. Mechanistically, we found
that this activity was mediated by androgen-stimulated recruit-
ment of hypophosphorylated retinoblastoma protein (Rb) to AR
binding sites and enhanced in PCa cells expressing higher level
of AR. Because androgens at intermediate levels can stimulate
rather than impair the cell cycle in the LNCaP PCa cell line, we
further explored AR regulation of these genes in LNCaP cells..
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Characterization of AR Transcriptional Repression Activity
(A and B) VCaP cells in androgen-deprived medium were treated with 10 nM DHT for 4 hr, followed by AR ChIP-seq. Peaks were identified using model-based
analysis for ChIP-seq (MACS) (p < 1015). Shown are GO analyses of (A) AR-activated versus (B) AR-repressed genes (based on binding within 20 kb of the TSS).
(C) qRT-PCR of the indicated genes in VCaP cells treated with 10 nM DHT for 0–24 hr.
(D) ChIP analyses for AR, p-Pol2, and H3K4me2 at the indicated loci in VCaP cells treated with 10 nM DHT for 4 hr.
(E) VCaP xenografts pre-castration (AD) or 4 days post-castration were analyzed by AR ChIP-qPCR at the indicated loci.
(legend continued on next page)
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Although the expression of DNA replication geneswas increased
after 24 hr of androgen stimulation, the initial and direct effect
of AR was, similarly, to suppress their transcription. The later
increased transcription of these genes in LNCaP cells was
associated with AR activation of metabolic genes and subse-
quent cyclin-dependent kinase (CDK) activation and Rb hyper-
phosphorylation. These findings demonstrate that AR has an
Rb-dependent anti-proliferative function and suggest that this
function may be therapeutically enhanced by combination treat-
ments that stimulate AR while repressing its growth-promoting
functions.
RESULTS
Global Assessment of Genes Directly Regulated by AR
We and others reported previously that treatment with androgen
(dihydrotestosterone [DHT]) could directly repress the expression
of genes, including AR, AKR1C3, andOPRK1 (a neuroendocrine-
related gene), in PCa cells (Cai et al., 2011; Zhao et al., 2012). To
further identify genes directly regulated by AR, we carried out AR
ChIP-seq in VCaP cells treatedwith 10 nMDHT for 4 hr (treatment
under these conditions prevents apoptosis but does not sub-
stantially stimulate proliferation) (GEO: GSE32345). This yielded
12,210 high-confidence binding peaks using a stringent threshold
(p < 1015) (Figure S1A). We next identified genes with AR binding
sites within 20 or 50 kb of their transcriptional start sites (TSSs), or
within gene bodies, whose mRNA levels were altered by 24-hr
DHT treatment (2-fold cutoff) in VCaP cells. By each criterion,
we found enrichment for AR binding sites and binding motifs in
association with androgen-stimulated genes (Figure S1B; Table
S1). There was less enrichment for AR binding sites in association
with androgen-repressed genes. This may reflect weaker AR
binding to a subset of androgen-repressed genes because the
average peak intensity in those gene loci was generally weaker
than in androgen-stimulated genes (although the difference was
not statistically significant) (Figure S1C). This lower enrichment
could also reflect indirect AR binding to some of these sites or
repression by other indirect mechanisms (Curtin et al., 2001;
Shah et al., 2003).
Genes Directly Repressed by AR Regulate DNA
Replication
Gene ontology (GO) analysis of androgen-stimulated genes with
associated ARbinding sites in VCaP cells showed enrichment for
lipid/sterol metabolism pathways, consistent with previous find-
ings (Figure 1A; Figure S1D; Cai et al., 2011; Massie et al., 2011;
Xu et al., 2006). In contrast, analysis of androgen-repressed
genes with AR binding sites revealed enrichment for genes
involved in DNA replication (Figure 1B; Figure S1E). Because
the average intensity of AR binding was generally weaker at
AR-repressed genes (Figure S1C), we reanalyzed the data using
less stringent thresholds (p < 105 for peak calling and 1.5-fold(F) Severe combined immunodeficiency (SCID) mice (n = 5) bearing recurrent
intraperitoneal [i.p.] injection) for 5 days. The mRNA extracted from tumor bio
pre-treatment.
Data in bar graphs represent mean ± SD of at least three biological repeats.
See also Figure S1.
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genes that have AR binding sites within 20 kb upstream of
TSSs or gene bodies. The GO analysis showed similar results
as using more stringent parameters (data not shown), and this
analysis with less stringent criteria identified 89 androgen-
repressed genes involved in DNA replication. The majority had
linked AR binding sites (77 of 89), consistent with direct repres-
sion by AR (Table S1).
These genes mediate a variety of DNA replication-related
functions, including DNA synthesis, modification, metabolism,
and repair. Significantly, 50 of 77 of these genes were overex-
pressed in a previously reported group of metastatic CRPC
versus primary PCa samples (Stanbrough et al., 2006), indicting
the importance of these DNA replication genes in driving PCa
progression (Table S1). The DHT-stimulated downregulation of
a subset of these genes was confirmed by qRT-PCR (Figure 1C).
We then selected a minichromosome maintenance complex
gene (MCM7) and a Fanconi anemia complementation group
gene (FANCI) for further validation (also including AKR1C3 and
OPRK1). ChIP-qPCR confirmed AR binding at the sites identified
by ChIP-seq for each gene and showed decreased Ser5-phos-
phorylated RNA polymearse 2 (pol II) (p-Pol2, a mark of tran-
scriptional activation) and decreased H3K4me2 upon DHT stim-
ulation (Figure 1D), consistent with transcriptional repression.
To determinewhether ARwas binding to these sites in vivo, we
examined the effects of ADT on AR occupancy in VCaP xeno-
grafts. Androgen deprivation led to marked decreases in AR
binding at all tested loci in vitro and in vivo (Figure S1F; Figure 1E).
Finally, to determine whether androgens could repress DNA
replication genes in vivo, we examined castration-resistant
VCaP xenografts before or after treatment with high-dose
testosterone (which causes a rapid reduction in tumor volume
in this model) (Cai et al., 2011). As shown in Figure 1F, except
for LMNB1, the expression of each gene examined was
decreased by testosterone. Finally, we examined whether AR
binds to those repressive sites in normal prostate and PCa cells
from human patient tissues using a public ChIP-seq database
(Pomerantz et al., 2015). In those samples, over 50% of the
DNA replication genes (as well as other AR-repressed genes)
consistently harbor nearby AR binding sites at the same location
as in DHT-treated VCaP cells (Figures S1G and S1H). Together,
these findings support the conclusion that AR functions as a
direct transcriptional repressor at these sites both in vitro and
in vivo.
ARRepression of DNA Replication Genes Is Mediated by
Recruitment of Rb
Many of these DNA replication-related genes are targets of E2F
and Rb (Dick and Rubin, 2013). Therefore, we hypothesized that
AR may increase the recruitment of Rb to these genes and
thereby enhance their Rb-mediated repression. Indeed, DHT
rapidly increased Rb binding at the major AR binding sites (S)VCaP xenografts were treated with 1 mg of testosterone per animal (daily
psies was analyzed by qRT-PCR, with post-treatment levels normalized to
Figure 2. AR Repression of DNA Replication Genes Is Mediated by Recruitment of Rb
(A) ChIP-qPCR for Rb recruitment by 10 nM DHT (4 or 24 hr) at the indicated loci in VCaP cells.
(B) ChIP-qPCR for Rb recruitment by DHT alone (4 hr) versus DHT plus 5 mM enzalutamide (pretreatment, 4 hr) in VCaP cells.
(C) SCIDmice bearing VCaP CRPC xenografts were treated with vehicle (n = 4) or 1 mg of testosterone (n = 4) for 1 week. Biopsies of tumor tissue were fixed and
subjected to ChIP-qPCR of Rb at the indicated loci.
(D) AR ChIP was performed first in VCaP cells treated with DHT for 4 hr, followed by Re-ChIP of Rb.
(E) Plasmids expressing Rb or AR fragments (hemagglutinin [HA]-tagged; FL, 1–919 amino acids [aa]; N, 1–539 aa; ND, 1–628 aa; DL, 538–919 aa; L, 662–919 aa)
were cotransfected in 293 cells. AR protein fragments were immunoprecipitated by anti-HA beads, followed by Rb immunoblotting.
(legend continued on next page)
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inMCM7 and BLM (which overlap with the promoters) as well as
in FANCI and LMNB1 (within the gene bodies), and this Rb
recruitment persisted at 24 hr (Figure 2A). DHT also stimulated
Rb binding at the promoter regions of FANCI and LMNB1 (P).
This AR binding and recruitment of Rb could be decreased by
the AR antagonist enzalutamide (Figure S2A; Figure 2B). To
further validate this Rb recruitment in vivo, we carried out Rb
ChIP in tissue samples from castration-resistant VCaP xeno-
grafts with short-term testosterone treatment. As seen in Fig-
ure 2C, Rb binding was increased upon testosterone treatment.
Finally, we assessed for histone deacetylases (HDACs), which
are recruited by Rb as mediators of gene repression. Binding
of HDAC1 and 2 was DHT-stimulated, and this recruitment led
to deacetylation of H3K27 (Figure S2B).
Using ChIP-Re-ChIP in VCaP cells, we next determined that AR
and Rb are associated in a complex at these repressive sites (Fig-
ure 2D). Experiments in cells overexpressingARandRbwere then
carried out to determine whether a specific AR domain mediates
the interaction. This indicated that Rb preferentially interacts with
an N-terminal region of AR (Figure 2E), consistent with a previous
study (Lu and Danielsen, 1998). However, we cannot exclude the
possibility that AR interaction with Rb is indirect and mediated or
enhanced by another protein or that binding of the endogenous
proteins is transient unless stabilized by chromatin binding.
We next treated VCaP cells with RB small interfering RNA
(siRNA) to determinewhether Rb contributes to the AR-mediated
repression of these genes. As expected, RB knockdown (Fig-
ure 2F) increased the expression of each gene in the absence
of DHT (Figure 2G). Moreover, the repression in response
to DHT was decreased in the Rb knockdown cells. Finally,
AR-mediated repression of OPRK1 (non-detectable Rb binding
site; Figure S3D) was not affected by RB siRNA.
We next examined C4-2 cells, a cell line derived from a CRPC
LNCaP xenograft that has increased AR expression and sensi-
tivity to low levels of androgen and whose proliferation can be
suppressed at high levels of androgen (Gregory et al., 2001).
C4-2 cells also exhibited androgen-repressed expression of
DNA replication genes (Figure 2H), and DHT stimulation of Rb
binding was similarly observed (Figure 2I). Therefore, we specu-
lated that impairing AR recruitment of Rb may decrease the abil-
ity of DHT to suppress C4-2 cell proliferation. As seen in Figures
2J and 2K, DHT treatment significantly decreased the S phase
fraction but did not suppress that in cells transfected with RB
siRNA.
Rb Binding Globally Associates with AR Transcriptional
Repression
To globally assess the overlap between AR and Rb binding, we
carried out Rb ChIP-seq in 10 nM DHT-treated (4 hr) VCaP cells(F and G) VCaP cells were transfected with non-target control (siNTC) or RB siRN
24 hr, followed by (F) immunoblotting for Rb and (G) qRT-PCR for the indicated
(H) qRT-PCR for expression of the indicated genes in C4-2 cells treated with 10
(I) ChIP-qPCR for Rb recruitment by 10 nM DHT (4 hr) at the indicated loci in C4
(J and K) C4-2 cells were transfected with siNTC or siRB for 2 days in hormone-re
then treated with 10 nM DHT for 24 hr, followed by (J) immunoblotting for Rb an
Data in bar graphs represent mean ± SD of at least three biological repeats.
See also Figure S2.
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As expected, these Rb binding sites were markedly enriched for
the E2F binding motif (Figure S3A), and analysis of the top 1,000
genes showed enrichment for genes mediating DNA replication
(Figure S3B). Significantly, a large portion of Rb binding sites
(6,056 of 9,797, 70%) overlapped with AR binding sites (Fig-
ure 3A), and these sites were similarly enriched for E2F binding
motifs (Figure 3B). Moreover, a higher intensity of AR binding
correlated with stronger Rb binding at these sites within AR-
repressed genes (Figure 3C). Among the 77 AR-repressed
DNA replication gene subset, 74 genes (95%) had Rb binding
sites, and 66 genes (85%) had AR and Rb overlapping binding
sites (Figures S3C and S3D).
We then performed a binding and expression target analysis
(BETA) (Wang et al., 2013) to globally determine the association
of Rb binding with AR regulation of gene expression. As seen in
Figure 3D, Rb unique binding sites (no AR binding, left) were only
weakly associated with AR-repressed genes. In contrast, AR-Rb
overlapping sites (center) were very highly associated with AR-
repressed genes, whereas AR unique sites (no Rb binding, right)
were most strongly associated with AR-activated genes. Collec-
tively, these gene-specific and global analyses of Rb and AR
binding sites strongly indicate that androgen-stimulated Rb
binding is a mechanismmediating AR-dependent transcriptional
repression.
AR Directly Represses and Indirectly Enhances
Expression of Genes Regulating DNA Replication in
LNCaP Cells
Although DNA replication genes were repressed by 24 hr of DHT
in VCaP and C4-2 cells, many were increased by treatment with
10 nM DHT at 24 hr in the LNCaP cell line (Figure 4A). However,
they were not increased at earlier time points that were sufficient
for induction of typical AR-regulated genes. We confirmed that
DHT did not increase expression of DNA replication genes in
LNCaP cells until 16–24 hr by qRT-PCR (Figure S4A). Protein
expression was also differentially regulated by androgen in
LNCaP versus VCaP cells (Figure S4B). As a control, OPRK1
was repressed similarly by androgens in both cell lines. This de-
layed stimulation suggested that these genes were not directly
induced by AR. To further test this hypothesis, we pre-treated
LNCaP cells with cycloheximide (CHX) to block new protein
synthesis prior to androgen treatment. Significantly, although
CHX did not prevent the DHT-stimulated increase in PLZF, it
prevented the increase in each of the DNA replication genes
examined (Figure S4C).
We next assessed AR binding and transcriptional activation of
these genes over a time course after DHT treatment. DHT stim-
ulated AR binding within 4 hr in LNCaP cells (Figure 4B), and thisA (siRB) for 2 days in hormone-depleted medium and then treated with DHT for
DNA replication genes.
nM DHT for 0–24 hr.
-2 cells.
duced medium (2% fetal bovine serum [FBS]/8% hormone-depleted FBS) and
d (K) flow cytometry cell cycle analysis.
Figure 3. Rb Binding Broadly Associates with AR-Mediated Transcriptional Repression
(A) Rb ChIP-seq in VCaP cells treated with 10 nM DHT for 4 hr. Peak calling was done using MACS (p < 105). Overlapping Rb and AR sites in DHT-treated VCaP
cells are shown.
(B) Motif enrichment analysis for AR and Rb overlapping sites using the Cistrome tool (the lowest p value is set to 1 3 1030).
(C) Heatmaps for AR and Rb binding intensity within the AR-repressed gene loci (ranking from high to low based on AR binding intensity).
(D) BETA analyses for the association of AR and Rb binding sites with expression of AR-activated versus -repressed genes (details can be found in the Sup-
plemental Experimental Procedures).
See also Figure S3.binding could be prevented by enzalutamide (Figure S4D). Sig-
nificantly, this AR binding was also associated with an initial
decrease of p-Pol2 (4–16 hr), which was only reversed after
24 hr of treatment. As controls, AR binding at PSA versus
OPRK1 gene loci led to progressive increases or decreases in
recruitment of p-Pol2, respectively.
Significantly, although 10 nM DHT stimulates proliferation of
LNCaP cells cultured in steroid-depleted medium, it does not
stimulate the proliferation of VCaP cells (Figure 4C). This may
reflect a VCaP requirement for additional growth factors that
are lost in steroid-depleted serum (Cai et al., 2011). As expected,
the time course for DHT stimulated induction of DNA replication
genes in LNCaP cells is similar to the time course for the increase
of S phase cells (Figure S4E). Consistent with these findings, Rb
phosphorylation was stimulated by 24-hr DHT treatment inLNCaP cells but remained unchanged in VCaP cells (Figure 4D;
Figures S4F and S4G). Importantly, this observation indicates
that decreased Rb phosphorylation is not a mechanism contrib-
uting to the androgen-stimulated increase in Rb binding to DNA
replication genes in VCaP or LNCaP cells.
We reported previously that AR stimulates G1/S cell cycle pro-
gression in LNCaP cells by increasing the transcription of multi-
ple genes involved in metabolism, with a subsequent increase in
TORC1 activity and translation of D cyclins (Xu et al., 2006).
Therefore, we considered that the increased expression of
DNA replication genes in LNCaP cells might be a downstream
consequence, rather than an upstream driver, of CDK activation
and Rb phosphorylation. To test this hypothesis, we treated
LNCaP cells with a CDK2 inhibitor, roscovitine, which effectively
prevented the DHT-stimulated increase in Rb phosphorylationCell Reports 17, 966–976, October 18, 2016 971
(Figure S4H). Significantly, this blocked the DHT-induced ex-
pression of DNA replication genes, but not PSA, indicating that
the DHT-mediated stimulation of these DNA replication genes
is a downstream consequence of increased G1/S CDK activity
(Figures S4I and S4J).
Because phosphorylation of Rb disrupts its binding to E2F, we
hypothesized that the initial DHT-stimulated recruitment of Rb, if
mediated jointly by AR and E2F, would be diminished by 24 hr in
LNCaP cells. Indeed, the Rb recruitment was lost at 24 hr (Fig-
ure 4E). This is in contrast with DHT-stimulated Rb binding in
VCaP cells that persisted at 24 hr (Figure 2A). Based on these re-
sults, we conclude that AR initially represses E2F-regulated
genes in LNCaP cells by enhancing the binding of hypophos-
phorylated Rb.
We further carried out RbChIP-seq in 10 nMDHT-treated (4 hr)
LNCaP cells and identified 21,932 binding peaks (Figure S4K).
The Rb binding profile in VCaP cells substantially overlapped
that in LNCaP cells (6,871 peaks,70% of total Rb binding sites
in VCaP). Among those overlapping Rb binding sites, 70%
(4,811 of 6,871) were linked with AR binding in VCaP cells, sug-
gesting that these sites may similarly be involved in mediating
AR repression activity in LNCaP cells. Interestingly, a large sub-
set of peaks (15,061) were unique, suggesting additional func-
tions in LNCaP cells. Significantly, for the 77 DNA replication
gene subset, all AR and Rb overlapping sites identified in
VCaP were also present in LNCaP cells (Figure S4L). Together,
these data indicate that a direct function of AR in LNCaP,
similarly to VCaP cells, is to repress expression of genes medi-
ating DNA replication. This repression may then be overcome
by AR-stimulated secondary mechanisms that lead to Rb
hyperphosphorylation.
AR Overexpression Enhances AR-Mediated Repression
of DNA Replication Genes
We next sought to further determine the basis for the differential
regulation of DNA replication genes in LNCaP versus VCaP and
C4-2 cells. One possible mechanism could be that repression is
favored by higher level of liganded AR. To test this, we examined
whether DNA replication genes would be repressed by higher
concentrations of DHT in LNCaP cells. Indeed, we observed a
biphasic response with maximum increases at 10 nM DHT after
24 hr, but expression did not decline below baseline at up to
1 mM DHT (Figure S4M).
Because both VCaP and C4-2 cells express higher levels of
AR relative to LNCaP (Figure S4N), we next hypothesized that
AR repression activity may be favored by overexpression of
AR protein. To test this, we stably overexpressed AR in
LNCaP cells (LN-AR) (Figure 4F) and assessed the effect of
DHT on DNA replication genes. Basal expression of each
DNA replication gene examined was increased in LN-AR cells
(Figure 4G), which is consistent with increased basal AR
activity and decreased dependence on exogenous androgens
for proliferation (Chen et al., 2004). However, in contrast to
the LNCaP control cells (LN-Ctrl), these DNA replication genes
were repressed by DHT in the LN-AR cells at 16–24 hr
(Figure 4G).
We next assessed the effects of AR overexpression on chro-
matin binding. DHT-stimulated AR binding to each of the genes972 Cell Reports 17, 966–976, October 18, 2016examined was increased and more persistent in the LN-AR cells
(Figure 4H), and p-Pol2 was decreased at 24 hr (Figure S4O).
Significantly, in contrast to diminished Rb binding at 24 hr of
DHT treatment in LNCaP cells (Figure 4E), Rb binding persisted
at 24 hr in LN-AR cells (Figure 4I). Taken together, these results
indicate that higher levels of AR in C4-2 and VCaP cells favor
repression.
Blocking G1/S-CDK Activity Enhances Androgen
Repression of Cell Proliferation in CRPC Cells
We next hypothesized that preventing Rb hyperphosphorylation
by blocking G1/S-CDK activity may further enhance the growth-
suppressive activity of androgens in CRPC models. Therefore,
we examined the combination effect of androgen and palboci-
clib, a CDK4/6 inhibitor (Finn et al., 2015), on expression of
DNA replication genes and on cell proliferation. As seen in Fig-
ures S4P and S4Q, palbociclib in C4-2 cells inhibited Rb phos-
phorylation and thereby enhanced AR-mediated repression of
DNA replication genes. Significantly, both cell cycle analysis
and proliferation assay showed that palbociclib treatment effec-
tively increased the growth-repressive effect of DHT (Figures 4J
and 4K; Figure S4R), suggesting a potential therapeutic strategy
for treating CRPC patients.
DISCUSSION
AR is a transcriptional activator but can also function as a tran-
scriptional repressor by direct and indirect mechanisms (Cai
et al., 2011; Zhao et al., 2012). Our previous analyses showed
that DHT-repressed genes in VCaP-derived models were highly
enriched in genes involved in DNA replication (Cai et al., 2011). In
this study, we examined AR ChIP-seq data and found closely
linked AR binding sites in a large fraction of DHT-repressed
DNA replication genes, supporting the conclusion that they are
directly repressed by AR. Moreover, although most of these
genes were increased by DHT in LNCaP cells, we confirmed
that the rapid direct action of DHT was still to repress these
genes and that their subsequent increase was indirect and due
to AR stimulation of other metabolic pathways. Overall, based
on these results, we conclude that AR functions directly as a
transcriptional repressor on DNA replication genes and suggest
that this reflects its normal differentiating function in prostate
epithelium. However, this growth-inhibitory function of AR is
clearly circumvented in PCa cells, where stimulatory effects of
AR on metabolic pathways may override its differentiating func-
tions and drive tumor growth.
Significantly, many genes involved in DNA replication are
regulated by Rb and E2F (Dick and Rubin, 2013). Rb had
been found previously to interact with AR, but it appeared to
act as an AR coactivator on androgen-stimulated genes in these
studies (Lu and Danielsen, 1998; Yeh et al., 1998). The basis for
this activity is not clear but could possibly reflect sequestration of
HDACs or other transcriptional corepressors. In other studies,
androgen-mediated repression of EZH2 and SKP2 was found
to be dependent on Rb or the related p107/p130, but these
effects were mediated by unclear indirect mechanisms (Bohrer
et al., 2010; Jiang et al., 2012). This report shows that AR en-
hances Rb binding to a series of E2F-regulated DNA replication
(legend on next page)
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genes, indicating that AR functions in concert with E2F to recruit
Rb and suppress these genes. Importantly, Rb ChIP-seq shows
substantial overlap between Rb and AR binding sites, and these
overlapping sites correlated with AR transcriptional repression
activity, suggesting a broad role of Rb in AR-mediated trans-
criptional repression. An AR-Rb-E2F-containing complex may
assemble directly on promoters that contain AR binding sites
or indirectly by chromatin looping in genes with AR binding sites
that are distal to the promoter and E2F sites. Importantly, this
recruitment of Rb is consistent with the ability of high-dose an-
drogens to suppress CRPC expressing a higher level of AR in
model systems and in a subset of patients (Schweizer et al.,
2015). Furthermore, our results suggest that high-dose androgen
therapy may be less effective in tumors that have downregulated
or lost Rb expression.
Among the genes directly repressed by AR were multiple
MCM genes, which are required to assemble origins of DNA
replication (Labib et al., 2000). Interestingly, AR has been re-
ported previously to function as a licensing factor that must be
degraded in early G1 phase to assemble these origins of replica-
tion so that high levels of androgen that maintain AR activity may
suppress DNA replication (D’Antonio et al., 2009). Although our
findings differ mechanistically from this previous study, our re-
sults similarly indicate that AR, by suppressing expression of
MCM genes, may impair origin-of-replication assembly. Many
genes that are activated for DNA replication are also involved
in DNA damage repair pathways, and a subset of these DNA
damage repair genes were found in a recent study to be tran-
scriptionally activated by AR in LNCaP cells (Polkinghorn et al.,
2013). These results are not inconsistent with our findings
because the reported increases were after 24–48 hr, and the
direct immediate effects of androgen were not assessed. How-
ever, mechanistically, our data would indicate that many of these
genes are not directly transcriptionally activated by AR but are
instead directly repressed, with their increased expression after
24 hr being through indirect mechanisms. In particular, based on
our data, we suggest that expression of at least a subset of these
DNA repair genes is induced as a downstream consequence of
G1/S CDK activation (Xu et al., 2006).
ADTs are initially effective in most patients, but by relieving
repression of multiple genes mediating DNA replication, they
may also be contributing to the eventual emergence of CRPC.
Interestingly, a recent study in the PTEN-deficient mouse PCa
model found that androgen ablation increased the eventualFigure 4. AR-Mediated Repression of DNAReplication Genes Is Circum
by AR Overexpression in CRPC Cells
(A) Expression of the 77 AR-repressed DNA replication gene subset and a group
(B) ChIP-qPCR at the indicated AR-dependent gene loci for AR and p-Pol2 bind
(C) LNCaP or VCaP cells in hormone-depleted medium were treated with 10 nM
(D) Immunoblotting for phosphorylated-Rb (Ser780) in LNCaP or VCaP cells trea
(E) ChIP-qPCR for Rb recruitment by DHT stimulation (0–24 hr) at the indicated l
(F) Immunoblotting for AR or FLAG in LN-Ctrl versus LN-AR cells.
(G) qRT-PCR for the indicated genes in LN-Ctrl versus LN-AR cells treated with
(H) ChIP-qPCR for DHT-stimulated (0–16 hr) AR binding in LN-Ctrl versus LN-AR
(I) ChIP-qPCR for DHT-stimulated Rb recruitment (0–24 hr) in LN-AR cells.
(J and K) C4-2 cells were treated with palbociclib (0.1 mM) or DHT (10 nM) for (J)
Data in bar graphs represent mean ± SD of at least three biological repeats.
See also Figure S4.
974 Cell Reports 17, 966–976, October 18, 2016emergence of invasive PCa (Jia et al., 2013). It is also intriguing
that androgen levels decline with age (Kaufman and Vermeulen,
2005). Although it has been suggested that a resulting increase in
the ratio of estrogen to testosterone may stimulate the develop-
ment of PCa, it is plausible that modest decreases in androgen
levels by themselves may relieve repression of androgen-
repressed genes and thereby contribute to PCa development.
Finally, the beneficial effects of 5a-reductase inhibitors in PCa
trials could possibly have been compromised by induction of
AR-repressed genes (Kang and Chung, 2013). Although it has
been long recognized that AR has both growth-promoting and
differentiating functions, we anticipate that further studies eluci-
dating the precise molecular basis for these functions will lead to
the development of more selective and effective AR-targeted
therapies.
EXPERIMENTAL PROCEDURES
ChIP
VCaP cell lines were treated with 10 nMDHT for 4 hr, followed by ChIP-seq an-
alyses (He et al., 2010). The antibodies and primers used for the ChIP analyses
are listed in the Supplemental Experimental Procedures.
RT-PCR and Immunoblotting
Gene expression was measured using TaqMan one-step RT-PCR reagents,
and the results were normalized to co-amplified GAPDH. For immunoblotting,
cells were lysed with RIPA buffer with protease inhibitors. The gels shown
are representative of at least three independent experiments. The primers/
probes and primary antibodies are listed in the Supplemental Experimental
Procedures.
VCaP Xenografts and LNCaP Stable Lines
Xenograft generation has been described previously (Cai et al., 2011). For
LNCaP-AR cells, FLAG-tagged AR was transfected in LNCaP cells, and stable
lines were established by G418 selection.
Statistical Analysis
The data in bar graphs represent mean ± SD of at least three biological re-
peats. Statistical analysis was performed using Student’s t test by comparing
treatment versus vehicle or otherwise as indicated. p < 0.05 (*) was considered
to be statistically significant.
Additional experimental procedures and methods are listed in the Supple-
mental Experimental Procedures.
ACCESSION NUMBERS
The accession number for the Rb ChIP-seq data reported in this paper is GEO:
GSE76141.vented by the Indirect Stimulatory Effect of Androgens but Enhanced
of AR-activated genes in LNCaP cells treated with 10 nM DHT for 0–24 hr.
ing in LNCaP cells treated with 10 nM DHT for 0–24 hr.
DHT for 24 hr, followed by cell cycle analysis.
ted with DHT for 0–24 hr.
oci in LNCaP cells.
DHT for 0–24 hr.
cells.
1 day followed by cell cycle analysis or (K) 0–4 days followed by cell counting.
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